Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 3/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470208 | 0.81 | FGFR2 (0.40) | FLT1FGFR2FLT3EGFRSYK | |
| SCHEMBL3468104 | 0.80 | FGFR2 (0.42) | FLT1FGFR2FLT3EGFRSYK | |
| SCHEMBL14537044 | 0.80 | AURKA (0.45) | FLT1FGFR2FLT3EGFRSYK | |
| SCHEMBL3469690 | 0.80 | PRKD1 (0.44) | FLT1FGFR2FLT3EGFRSYK | |
| SCHEMBL8241606 | 0.80 | AURKA (0.58) | FGFR2FLT3EGFRSYKMAPKAPK5 | |
| SCHEMBL3470478 | 0.80 | MAPKAPK5 (0.43) | FLT1FGFR2FLT3EGFRSYK | |
| SCHEMBL3470512 | 0.79 | SYK (0.49) | FGFR2FLT3EGFRSYKPRKD1 | |
| SCHEMBL3469529 | 0.79 | PRKD1 (0.41) | FLT1FGFR2FLT3EGFRSYK | |
| SCHEMBL1674087 | 0.78 | MAPKAPK5 (0.60) | FGFR2FLT3EGFRSYKMAPKAPK5 | |
| SCHEMBL3469745 | 0.78 | ABL1 (0.51) | FGFR2FLT3EGFRSYKCACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2471529-A2 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | Emory University (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | FLT1 1771/4885FGFR2 2099/4885FLT3 303/4885 |
| US-20100144743-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF TYROSINE KINASES | ABL1, LCK, SRC | FLT1 332/4885FGFR2 549/4885FLT3 10/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | FLT1 1771/4885FGFR2 2099/4885FLT3 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.